Four Major Clinical Trial Readouts To Watch Out For In Q2
Four prominent drug candidates are expecting topline mid- or late-stage data over the next few months. With the help of Biomedtracker's Q2 Outlook Report, we take a look at the assets that could help validate some of the companies developing them, from oncology to psychiatry.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: GSK pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim’s hopes for Jardiance; Japan rebuilds generic supplies; and a look at key upcoming trial readouts.
FDA wants another trial in ultra-orphan Barth syndrome, but could not identify a feasible design – so Stealth submitted the NDA anyways, based on a retrospective natural history control trial
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Tarpeyo following delays related to manufacturing questions.